These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 28818402)

  • 1. Association of hemolysis with high dose intravenous immunoglobulin therapy in pediatric patients: An open-label prospective trial.
    Akman AO; Kara FK; Koksal T; Cakir BC; Karagol C; Sayli T
    Transfus Apher Sci; 2017 Aug; 56(4):531-534. PubMed ID: 28818402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous immunoglobulin-related hemolysis in patients treated for Kawasaki disease.
    Luban NL; Wong EC; Henrich Lobo R; Pary P; Duke S
    Transfusion; 2015 Jul; 55 Suppl 2():S90-4. PubMed ID: 26174904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemolytic anemia following high dose intravenous immunoglobulin in patients with chronic neurological disorders.
    Markvardsen LH; Christiansen I; Harbo T; Jakobsen J
    Eur J Neurol; 2014; 21(1):147-52. PubMed ID: 24180709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemolysis related to intravenous immunoglobulins is dependent on the presence of anti-blood group A and B antibodies and individual susceptibility.
    Mielke O; Fontana S; Goranova-Marinova V; Shebl A; Spycher MO; Wymann S; Durn BL; Lawo JP; Hubsch A; Salama A
    Transfusion; 2017 Nov; 57(11):2629-2638. PubMed ID: 28840942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemolytic events associated with intravenous immune globulin therapy: a qualitative analysis of 263 cases reported to four manufacturers between 2003 and 2012.
    Berg R; Shebl A; Kimber MC; Abraham M; Schreiber GB
    Transfusion; 2015 Jul; 55 Suppl 2():S36-46. PubMed ID: 26174896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective observational study of the incidence, natural history, and risk factors for intravenous immunoglobulin-mediated hemolysis.
    Pendergrast J; Armali C; Callum J; Cserti-Gazdewich C; Jiwajee A; Lieberman L; Lau W; Lin Y; Parmar N; Pavenski K; Riden LS; Shehata N; Willie-Ramharack K; Tomlinson G; Tong TN; Binnington B; Branch DR;
    Transfusion; 2021 Apr; 61(4):1053-1063. PubMed ID: 33433931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of anti-D immunoglobulin versus low-dose intravenous immunoglobulin in the treatment of childhood chronic idiopathic thrombocytopenic purpura.
    El Alfy MS; Mokhtar GM; El-Laboudy MA; Khalifa AS
    Acta Haematol; 2006; 115(1-2):46-52. PubMed ID: 16424649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients.
    Kahwaji J; Barker E; Pepkowitz S; Klapper E; Villicana R; Peng A; Chang R; Jordan SC; Vo AA
    Clin J Am Soc Nephrol; 2009 Dec; 4(12):1993-7. PubMed ID: 19833910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Meta analysis of the effect of immunoglobulin infusion on neonatal isoimmune hemolytic disease caused by blood group incompatibility].
    Li ZH; Wang J; Chen C
    Zhonghua Er Ke Za Zhi; 2010 Sep; 48(9):656-60. PubMed ID: 21092522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose intravenous immunoglobulin is strongly associated with hemolytic anemia in patients with Kawasaki disease.
    Nolan BE; Wang Y; Pary PP; Luban NLC; Wong ECC; Ronis T
    Transfusion; 2018 Nov; 58(11):2564-2571. PubMed ID: 30265742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of isoagglutinins in intravenous immunoglobulin-related hemolysis.
    Bellac CL; Hottiger T; Jutzi MP; Bögli-Stuber K; Sänger M; Hanschmann KM; Keller-Stanislawski B; Funk MB
    Transfusion; 2015 Jul; 55 Suppl 2():S13-22. PubMed ID: 26174892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood group A mothers are more likely to develop anemia during antenatal intravenous immunoglobulin treatment of fetal and neonatal alloimmune thrombocytopenia.
    Lakkaraja M; Jin JC; Manotas KC; Vinograd CA; Ferd P; Gabor J; Wissert M; Berkowitz RL; McFarland JG; Bussel JB
    Transfusion; 2016 Oct; 56(10):2449-2454. PubMed ID: 27611703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute hemolysis after intravenous immunoglobulin amid host factors of ABO-mismatched bone marrow transplantation, inflammation, and activated mononuclear phagocytes.
    Michelis FV; Branch DR; Scovell I; Bloch E; Pendergrast J; Lipton JH; Cserti-Gazdewich CM
    Transfusion; 2014 Mar; 54(3):681-90. PubMed ID: 23829192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible mechanisms for intravenous immunoglobulin-associated hemolysis: clues obtained from review of clinical case reports.
    Padmore R
    Transfusion; 2015 Jul; 55 Suppl 2():S59-64. PubMed ID: 26174898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemolytic adverse effects of intravenous immunoglobulin: modeling predicts risk reduction with anti-A/B immunoaffinity chromatography and to a lesser extent with anti-A donor screening.
    Mallick R; Hubsch A; Barnes DG
    Transfusion; 2018 Dec; 58(12):2752-2756. PubMed ID: 30284263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and risk factors for intravenous immunoglobulin-related hemolysis: A systematic review of clinical trial and real-world populations.
    Cuesta H; El Menyawi I; Hubsch A; Hoefferer L; Mielke O; Gabriel S; Shebl A
    Transfusion; 2022 Sep; 62(9):1894-1907. PubMed ID: 35916266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specifications for anti-A and anti-B in intravenous immunoglobulin: history and rationale.
    Thorpe SJ
    Transfusion; 2015 Jul; 55 Suppl 2():S80-5. PubMed ID: 26174902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous immunoglobulin-induced haemolysis: a case report and review of the literature.
    Desborough MJ; Miller J; Thorpe SJ; Murphy MF; Misbah SA
    Transfus Med; 2014 Aug; 24(4):219-26. PubMed ID: 24164446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haemolysis after treatment with intravenous immunoglobulin due to anti-A.
    Morgan S; Sorensen P; Vercellotti G; Zantek ND
    Transfus Med; 2011 Aug; 21(4):267-70. PubMed ID: 21605202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The utility of a monocyte monolayer assay in the assessment of intravenous immunoglobulin-associated hemolysis.
    Tong TN; Blacquiere M; Sakac D; Burke-Murphy E; Yi Q; Callum J; Cserti-Gazdewich C; Parmar N; Shehata N; Pavenski K; Lau W; Lin Y; Lieberman L; Branch DR; Pendergrast J
    Transfusion; 2020 Dec; 60(12):3010-3018. PubMed ID: 33091964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.